Home Clinical Trials Novo Nordisk, Anthem’s HealthCore Launch Pragmatic Real-World Type 2 Diabetes Drug Trial

Novo Nordisk, Anthem’s HealthCore Launch Pragmatic Real-World Type 2 Diabetes Drug Trial

123
0

HealthCore, Inc., the outcomes research subsidiary of Anthem, Inc. and Novo Nordisk Inc., which manufacturers the once weekly GLP-1 receptor agonist Ozempic (semaglutide), are working together to launch the first of its kind pragmatic study to understand the benefits of semaglutide as compared with all other available diabetes drugs in a real-world pragmatic clinical trial for Type 2 diabetes – one of the nation’s fastest growing chronic diseases. The randomized Ozempic pragmatic trial, “Long-term comparative effectiveness of once weekly SEmaglutide versus standard of care in a real world adult US population with type 2 diabetes – a randomized PRAgmatic clinical trial,” or SEPRA, will compare the long-term effectiveness of Ozempic to potentially 40 other medications among 2,250 adult consumers with Type 2 diabetes. The trial aims to learn whether Ozempic leads to better outcomes or impacts the need for health services compared to other FDA-approved drugs to treat diabetes.

LEAVE A REPLY

Please enter your comment!
Please enter your name here

This site uses Akismet to reduce spam. Learn how your comment data is processed.